BioSpace News Archive

Shanghai Operation Robot Co.,Ltd announced the results of its initial clinical trial of ERCP robot in biliary stent placement surgery.

Verona Pharma plc, announces that senior management will participate in the following conferences in November 2022.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it will report financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022, after the U.S. financial markets close.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open.

Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets.

EyePoint Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

AIM ImmunoTech Inc. announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to Ampligen® for the treatment of Ebola virus disease.

Tiziana Life Sciences Ltd. announced completion of enrollment of the first patient cohort in its Intermediate-Size Patient Population Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients has quickly been completed, following the start of enrollment announced last week.

Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2022 financial results.